Elizabeth Garrett-Mayer to Treatment Outcome
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Treatment Outcome.
Connection Strength
0.264
-
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15; 14(10):3077-82.
Score: 0.033
-
Smoking status and symptom burden in surgical head and neck cancer patients. Laryngoscope. 2017 01; 127(1):127-133.
Score: 0.014
-
Rates and predictors of adherence to psychotropic medications in children with autism spectrum disorders. J Autism Dev Disord. 2014 Nov; 44(11):2931-48.
Score: 0.013
-
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
Score: 0.012
-
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
Score: 0.011
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.010
-
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. 2011 May; 127(1):153-62.
Score: 0.010
-
High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer. J Med Imaging Radiat Oncol. 2010 Dec; 54(6):554-61.
Score: 0.010
-
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
Score: 0.010
-
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8.
Score: 0.009
-
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976). 2009 Sep 01; 34(19):2096-103.
Score: 0.009
-
Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 01; 115(11):2514-22.
Score: 0.009
-
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10; 27(17):2816-22.
Score: 0.009
-
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2008 May 07; 100(9):681-2; author reply 682-3.
Score: 0.008
-
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep; 32(9):1439-47.
Score: 0.008
-
Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg. 2008 Jan; 143(1):29-34; discussion 35.
Score: 0.008
-
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. 2008 Jan 08; 105(1):288-93.
Score: 0.008
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 01; 13(21):6396-403.
Score: 0.008
-
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. 2007 Sep 01; 110(5):1115-24.
Score: 0.008
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.008
-
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar; 69(3):526-31.
Score: 0.008
-
How should treatment decisions be made for incapacitated patients, and why? PLoS Med. 2007 Mar; 4(3):e35.
Score: 0.008
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94.
Score: 0.007
-
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2005 Jan; 11(1):39-46.
Score: 0.006
-
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):990-1000.
Score: 0.006
-
Preoperative predictors of blood transfusion in colorectal cancer surgery. J Gastrointest Surg. 2002 Sep-Oct; 6(5):753-62.
Score: 0.006
-
Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments. J Spinal Disord. 2001 Oct; 14(5):427-33.
Score: 0.005
-
Cauda equina syndrome secondary to lumbar disc herniation: a meta-analysis of surgical outcomes. Spine (Phila Pa 1976). 2000 Jun 15; 25(12):1515-22.
Score: 0.005